Sept. 24, 2007 - Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) : the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures... Progen's Press release [PDF] -
Blog Archive
-
▼
2007
(90)
-
▼
September
(43)
- Oncolytics Biotech, Phase Ia/Ib Combination REOLYS...
- Gene Express, Lung Cancer Diagnostic
- The SFDA of the PRC Grants Immtech Fast Track Status
- Spiration, U.S. Pivotal Trial of Minimally Invasiv...
- Alkermes and Indevus, Positive Results from Phase ...
- Curis , Development Candidate CUDC-101 and Its Tar...
- Inspired Technologies, FDA 510(k) Approval for the...
- Pharmacopeia , Phase 1 Clinical Trials of a poten...
- Cell Therapeutics, Gender-Specific Phase III Trial...
- Encysive Pharmaceuticals, Phase III Study With The...
- Progen , PI-88 Phase 2 Lung Cancer Results
- ImClone , Expands IMC-A12 Development with Ten New...
- Lilly, ALIMTA® (pemetrexed for injection) for Firs...
- Nymox Saliva Test, Saliva NicAlert, test for tobac...
- OSI Pharmaceuticals, Patent Term Extension for Tar...
- LigoCyte , to develop therapies targeting CD103 fo...
- Forest Laboratories, single doses of inhaled aclid...
- Biomoda, Inc. and TriCore, detection of early lung...
- Replidyne's Phase III clinical program for the tre...
- Exelixis Submits XL880 Diligence Report to GlaxoSm...
- Genmab,Target and Development Plans for HuMax-Inflam
- Illumina, Genotyping Service Agreement with Leadin...
- Seegene, Diagnostic Test Kit Capable of Detecting ...
- GeneGo and the Cystic Fibrosis Foundation Collabor...
- ImClone and BMS, ERBITUX ,Primary Endpoint of Incr...
- China Kangtai Cactus Biotech, Cactus Health Cigare...
- Novelos Therapeutics, 5th U.S. Patent
- Accuray, FDA Clearance for New Dose Calculation Te...
- TapImmune, Initiation of Testing on Novel Cancer V...
- Perceptronix, Launch of LungSign(TM)
- TOPIGEN Pharmaceuticals, TPI 1020 Into Phase 2 Dev...
- OSI Pharmaceuticals, Data Presented on Tarceva(R) ...
- superDimension, First Device to Enable Minimally-I...
- Aradigm and CyDex, Development Collaboration Agree...
- Amgen , Aranesp(R) Study Showing No Negative Impac...
- Idera Pharmaceuticals, Phase 1 Study Evaluating
- Introgen Therapeutics, Immunotherapy Drug [p53] C...
- Pharmacyclics , Phase 2 Data With Xcytrin(R) in Re...
- Biomira Inc., Stimuvax(R) Phase II data highlight,...
- Nabi Biopharmaceuticals, Positive NicVAX (Nicotine...
- Poniard Pharmaceuticals Picoplatin for Treatment o...
- Pfizer Oncology, Advanced Non-Small Cell Lung Cancer
- A blog about Lung's Diseases
-
▼
September
(43)
Sep 25, 2007
Progen , PI-88 Phase 2 Lung Cancer Results
Sept. 24, 2007 - Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) : the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures... Progen's Press release [PDF] -
